5,5-Bis(4-pyridinylmethyl)indeno-[1,2-b]-pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5,5-Bis(4-pyridinylmethyl)indeno-[1,2-b]-pyridine
• 英文别名: 5,5-Bis(4-pyridinylmethyl)-indeno-[1,2-b]pyridine；5,5-bis(pyridin-4-ylmethyl)indeno[1,2-b]pyridine
• 化学式: C₂₄H₁₉N₃
• 分子量: 349.435
• InChiKey: AVQJIVUHTCZMKP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-氯甲基吡啶 、 5H-茚并[1,2-b]吡啶 在 乙醇 、 sodium hydride 作用下， 生成 5,5-Bis(4-pyridinylmethyl)indeno-[1,2-b]-pyridine
  参考文献：
  名称：

  2-Fluoro-4-pyridinylmethyl Analogues of Linopirdine as Orally Active Acetylcholine Release-Enhancing Agents with Good Efficacy and Duration of Action

  摘要：

  In an effort to improve the pharmacokinetic and pharmacodynamic properties of the cognition-enhancer linopirdine (DuP 996), a number of core structure analogues were prepared in which the 4-pyridyl pendant group was systematically replaced with 2-fluoro-4-pyridyl. This strategy resulted in the discovery of several compounds with improved activity in acetylcholine (ACh) release-enhancing assays, in vitro and in vivo. The most effective compound resulting from these studies, 10,10-bis[(2-fluoro-4-pyridinyl)methyl]-9(10H)-anthracenone (9), is between 10 and 20 times more potent than linopirdine in increasing extracellular hippocampal ACh levels in the rat with a minimum effective dose of 1 mg/kg. In addition to superior potency, 9 possesses an improved pharmacokinetic profile compared to that of linopirdine. The half-life of 9 (2 h) in rats is 4-fold greater than that of linopirdine (0.5 h), and it showed a g-fold improvement in brain-plasma distribution over linopirdine. On the basis of its pharmacologic, pharmacokinetic, absorption, and distribution properties, 9 (DMP543) has been advanced for clinical evaluation as a potential palliative therapeutic for treatment of Alzheimer's disease.

  DOI：

  10.1021/jm9803424

文献信息

• .alpha.,.alpha.-disubstituted aromatics and heteroaromatics as cognition
  申请人：The DuPont Merck Pharmaceutical Co.

  公开号：US05173489A1

  公开（公告）日：1992-12-22

  Cognitive defeciencies or neurological dysfunction in mammals are treated with .alpha.,.alpha.-disubstituted aromatic or heteroaromatic compounds. The compounds have the formula: ##STR1## or a salt thereof wherein X and Y are taken together to form a saturated or unsaturated carbocyclic or heterocyclic first ring and the shown carbon in said ring is .alpha. to at least one additional aromatic ring or heteroaromatic ring fused to the first ring; one of Het.sup.1 is 2, 3 or 4-pyridyl or 2, 4, or 5-pyrimidinyl and the other is selected from (a) 2, 3, or 4-pyridyl, (b) 2, 4, or 5-pyrimidinyl, (c) 2-pyrazinyl, (d) 3, or 4-pyridazinyl, (e) 3, or 4-pyrazolyl, (f) 2, or 3-tetrahydrofuranyl, and (g) 3-thienyl.

  哺乳动物中的认知缺陷或神经功能障碍可用α，α-二取代芳香或杂芳化合物进行治疗。这些化合物的化学式为：##STR1##或其盐，其中X和Y一起形成饱和或不饱和的碳环或杂环第一环，所示的碳在该环中为至少一个额外的芳香环或杂芳环的α位融合到第一环；Het.sup.1中的一个是2，3或4-吡啶基或2，4或5-嘧啶基，另一个选自(a)2，3或4-吡啶基，(b)2，4或5-嘧啶基，(c)2-吡嗪基，(d)3或4-吡啶嗪基，(e)3或4-吡唑基，(f)2或3-四氢呋喃基，和(g)3-噻吩基。
• .alpha., .alpha.-disubstituted aromatics and heteroaromatics as
  申请人：The Du Pont Merck Pharmaceutical Company

  公开号：US05300642A1

  公开（公告）日：1994-04-05

  Cognitive defeciencies or neurological dysfunction in mammals are treated with .alpha.,.alpha.-disubstituted aromatic or heteroaromatic compounds. The compounds have the formula: ##STR1## or a salt thereof wherein X and Y are taken together to form a saturated or unsaturated carbocyclic or heterocyclic first ring and the shown carbon in said ring is .alpha. to at least one additional aromatic ring or heteroaromatic ring fused to the first ring; one of Het.sup.1 or Het.sup.2 is 2, 3, or 4-pyridyl or 2, 4, or 5-pyrimidinyl and the other is selected from (a) 2, 3, or 4-pyridyl, (b) 2, 4, or 5-pyrimidinyl, (c) 2-pyrazinyl, (d) 3, or 4-pyridazinyl, (e) 3, or 4-pyrazolyl, (f) 2, or 3-tetrahydrofuranyl, and (g) 3-thienyl.

  哺乳动物中的认知缺陷或神经功能障碍可用.alpha.，.alpha.-二取代芳香族或杂芳香族化合物进行治疗。该化合物的化学式为：##STR1## 或其盐，其中X和Y共同形成饱和或不饱和的碳环或杂环的第一个环，所示的碳原子在该环中是.alpha.至少一个与第一个环融合的芳香环或杂芳香环；Het.sup.1或Het.sup.2中的一个是2，3或4-吡啶基或2，4或5-嘧啶基，另一个选择自(a)2，3或4-吡啶基，(b)2，4或5-嘧啶基，(c)2-吡嗪基，(d)3或4-吡嗪啉基，(e)3或4-嘧唑基，(f)2或3-四氢呋喃基和(g)3-噻吩基。
• Process for preparing alpha,alpha-disubstituted aromatics and heteroaromatics as cognition enhancers
  申请人：THE DU PONT MERCK PHARMACEUTICAL COMPANY

  公开号：EP0532054A1

  公开（公告）日：1993-03-17

  Cognitive defeciencies or neurological dysfunction in mammals are treated with α,α-disubstituted aromatic or heteroaromatic compounds. The compounds have the formula: or a salt thereof    wherein X and Y are taken together to form a saturated or unsaturated carbocyclic or heterocyclic first ring and the shown carbon in said ring is α to at least one additional aromatic ring or heteroaromatic ring fused to the first ring;    one of Het¹ or Het² is 2, 3, or 4-pyridyl or 2, 4, or 5-pyrimidinyl and the other is selected from (a) 2, 3, or 4-pyridyl, (b) 2, 4, or 5-pyrimidinyl, (c) 2-pyrazinyl, (d) 3, or 4-pyridazinyl, (e) 3, or 4-pyrazolyl, (f) 2, or 3-tetrahydrofuranyl, and (g) 3-thienyl.

  α，α-二取代芳香族或杂芳族化合物可治疗哺乳动物的认知缺陷或神经功能障碍。这些化合物的化学式如下 或其盐 其中 X 和 Y 共同形成饱和或不饱和碳环或杂环的第一环，所述环中所示碳与融 入第一环的至少一个附加芳环或杂芳环相连； Het¹ 或 Het² 中的一个是 2、3 或 4-吡啶基或 2、4 或 5-嘧啶基，另一个选自以下各项 (a) 2、3 或 4-吡啶基、 (b) 2、4 或 5-嘧啶基、 (c) 2-吡嗪基、 (d) 3 或 4-哒嗪基、 (e) 3 或 4-吡唑基、 (f) 2 或 3-四氢呋喃基，以及 (g) 3-噻吩基。
• Alpha,Alpha-disubstituted aromatics and heteroaromatics as cognition enhancers
  申请人：THE DU PONT MERCK PHARMACEUTICAL COMPANY

  公开号：EP0311010B1

  公开（公告）日：1994-02-02
• US5173489A
  申请人：——

  公开号：US5173489A

  公开（公告）日：1992-12-22